Surmodics
SRDX
SRDX was delisted on the 18th of November, 2025.
1 hedge funds and large institutions have $83 invested in Surmodics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 142 closing their positions.
80.75% less ownership
Funds ownership: 80.75% → 0% (-81%)
99% less funds holding
Funds holding: 146 → 1 (-145)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $345M → $83 (-$345M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 142
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$34.3M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$26.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.2M |
| 4 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
-$18.2M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$16M |
SRDX Hedge Fund Activity: Q4 2025 in Review
1 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Surmodics (SRDX) for Q4 2025, worth a combined $83 — down 100% from $345M a quarter earlier.
Sellers outnumbered buyers: 142 funds closed out of SRDX and 0 opened new positions — a net loss of 142 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $34.3M sold.
- 1 institutional investor held Surmodics (SRDX) as of Q4 2025, down from 146 in Q3 2025.
- Funds reported $83 of Surmodics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Surmodics positions in Q4 2025 and 142 closed out, a net change of -142 holders.
- The largest Surmodics seller in Q4 2025 was BlackRock, an estimated $34.3M sold.
Based on aggregated 13F filings for Q4 2025.